



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
KUFER et al.

Serial No.: 09/403,107

Filed: October 14, 1999

For: NOVEL METHOD FOR THE  
PRODUCTION OF ANTIHUMAN  
ANTIGEN RECEPTORS AND USES  
THEREOF

Group Art Unit: 1642

Examiner: Larry Helms

Atty. Dkt. No.: DEBE:017US/SLH

CERTIFICATE OF FACSIMILE TRANSMISSION  
37 C.F.R. § 1.8

I certify that this correspondence is being transmitted to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450, facsimile number (703) 872-9306 on the date  
below:

March 9, 2006  
Date

Steven L. Highlander

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO  
ACID SEQUENCE DISCLOSURES**

**Mail Stop Sequence**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is submitted in response to the Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated February 7, 2006, for which the thirty day date for response is March 9, 2006.


No fees are believed to be due in connection with the instant paper, however, should such fees be due, consider this paragraph a request and authorization to withdraw

the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski, L.L.P.  
Account No. 50-1212/DEBE:017US/SLH.

As requested in the Notice to Comply with Requirement for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, Applicants submit herein a Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement Under 37 C.F.R. § 1.821(g), a paper copy of Sequence Listing and CD-Rom.

The Examiner is invited to contact the undersigned at (512) 536-3085 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI, L.L.P.  
600 Congress Ave., Ste. 1900  
Austin, Texas 78701  
(512) 536-3085

Date: March 9, 2006

<b>TRANSMITTAL FORM</b> Total Number of Pages in this Submission : _____	<b>Application Number:</b>	09/403,107
	<b>Filing Date:</b>	October 14, 1999
	<b>First Named Inventor:</b>	Kufer
	<b>Art Unit:</b>	1642
	<b>Examiner Name:</b>	Larry Helms
	<b>Attorney Docket Number:</b>	DEBE:017US

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Form PTO-1449 <input type="checkbox"/> References _____ <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts/Requirements <input type="checkbox"/> Declaration(s) _____ <input type="checkbox"/> Copy of Notice of Missing Parts/Requirements	<input type="checkbox"/> Drawings(s) _____ <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Statement under 37 CFR §3.73(b) <input type="checkbox"/> Designation of Patent Practitioners <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input checked="" type="checkbox"/> CD, Number CD(s) 1 <input type="checkbox"/> Landscape Table on CD <input checked="" type="checkbox"/> Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below) <input type="checkbox"/> Check in the amount of \$ <input checked="" type="checkbox"/> Authorized to be charged to deposit account if check insufficient or inadvertently omitted Deposit account number: <u>50-1212/DEBE:017US/SLH</u> <input type="checkbox"/> Sequence Statement <input checked="" type="checkbox"/> Paper Copy of Sequence Listing <input checked="" type="checkbox"/> Computer Readable Form (CRF) <input checked="" type="checkbox"/> Postcard <input checked="" type="checkbox"/> Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures <input checked="" type="checkbox"/> Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g).
---	--	--

**Remarks:** If the check is inadvertently omitted or additional fees under 37 C.F.R. §§ 1.16 to 1.21 are required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/DEBE:017US/SLH.


**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

<b>Firm Name</b>	Fulbright & Jaworski L.L.P.	<b>Customer Number</b>	32425
<b>Signature</b>			
<b>Printed Name</b>	Steven L. Highlander	<b>Reg. No.</b>	37,642
<b>Date</b>	March 9, 2006		

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

<b>Signature</b>			
<b>Typed or Printed Name</b>	Steven L. Highlander	<b>Date</b>	March 9, 2006



Application No. 09/403,107

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☒ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**